How Will the Market React to Ideaya Biosciences Inc (IDYA) Stock Getting a Bearish Rating

The market has been down on Ideaya Biosciences Inc (IDYA) stock recently. IDYA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Ideaya Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IDYA!

See Full IDYA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IDYA Stock Today?

Ideaya Biosciences Inc (IDYA) stock is trading at $10.75 as of 3:54 PM on Tuesday, Aug 16, a rise of $0.55, or 5.39% from the previous closing price of $10.20. The stock has traded between $10.00 and $10.82 so far today. Volume today is elevated. So far 1,380,393 shares have traded compared to average volume of 291,731 shares.

More About Ideaya Biosciences Inc

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Click Here to get the full Stock Report for Ideaya Biosciences Inc stock.